Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at [email protected]

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
04/05 Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients W..
04/04 Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Del..
04/04 Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of..
03/23 IMMUNOMEDICS : Announces Publication of Results in Journal of Clinical Oncology,..
03/16 IMMUNOMEDICS,INC. (NASDAQ : IMMU) Files An 8-K Submission of Matters to a Vote o..
03/16 IMMUNOMEDICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
03/16 IMMUNOMEDICS : Submission of Matters to a Vote of Security Holders (form 8-K/A)
03/15 IMMUNOMEDICS : Announces publication of results in journal of clinical oncology,..
03/10 IMMUNOMEDICS, INC. : Markets Rally Late to Close in the Green: Today's Research ..
03/10 HERE’S WHAT’S MOVING IMM : IMMU) and Ocera Therapeutics Inc (NASDAQ:..
More news
Sector news : Biotechnology & Medical Research - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
04/21 Midday Gainers / Losers
04/21 Immunomedics off 13% on no ASCO update on IMMU-132
04/10 After Hours Gainers / Losers
03/14 WHY SHOULD INVESTORS CONSIDER AN ALL : A Sector Analysis
03/10 Activist Investor Puts Immunomedics Phase III In Play
Advertisement
Financials ($)
Sales 2017 15,1 M
EBIT 2017 -48,0 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 40,4x
Capi. / Sales 2018 9,22x
Capitalization 608 M
More Financials
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 7,50 $
Spread / Average Target 31%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Cynthia L. Sullivan President, Chief Executive Officer & Director
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President-Finance
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.56.13%608
INCYTE CORPORATION23.95%25 426
QUINTILES IMS HOLDINGS..10.82%19 884
LONZA GROUP AG17.13%11 836
SEATTLE GENETICS, INC.29.43%9 741
CELLTRION, INC.--.--%9 653
More Results